22-Apr-2024
No headlines found.
Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria
Globe Newswire (Thu, 25-Jan 4:29 PM ET)
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
Titan Pharmaceuticals trades on the NASDAQ stock market under the symbol TTNP.
As of April 22, 2024, TTNP stock price declined to $7.01 with 601 million shares trading.
TTNP has a beta of -0.64, meaning it tends to be less sensitive to market movements. TTNP has a correlation of 0.01 to the broad based SPY ETF.
TTNP has a market cap of $6.41 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, TTNP stock traded as high as $62.00 and as low as $5.00.
The top ETF exchange traded funds that TTNP belongs to (by Net Assets): VXF.
TTNP stock has underperformed the market in the last year with a return of -55.9%, while SPY returned +22.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in TTNP shares. However, TTNP has outperformed the market in the last 3 month and 2 week periods, returning +14.0% and +2.3%, while SPY returned +3.9% and -3.6%, respectively. This indicates TTNP has been having a stronger performance recently.
TTNP support price is $6.81 and resistance is $7.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TTNP stock will trade within this expected range on the day.